DE69516075D1 - Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen - Google Patents

Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen

Info

Publication number
DE69516075D1
DE69516075D1 DE69516075T DE69516075T DE69516075D1 DE 69516075 D1 DE69516075 D1 DE 69516075D1 DE 69516075 T DE69516075 T DE 69516075T DE 69516075 T DE69516075 T DE 69516075T DE 69516075 D1 DE69516075 D1 DE 69516075D1
Authority
DE
Germany
Prior art keywords
branched
straight
alkyl
phenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69516075T
Other languages
English (en)
Other versions
DE69516075T2 (de
Inventor
Neil Clayton Bodick
Franklin Porter Bymaster
Walter William Offen
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/332,186 external-priority patent/US5488056A/en
Priority claimed from US08/336,589 external-priority patent/US5484794A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69516075D1 publication Critical patent/DE69516075D1/de
Publication of DE69516075T2 publication Critical patent/DE69516075T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69516075T 1994-10-31 1995-10-30 Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen Expired - Fee Related DE69516075T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/332,186 US5488056A (en) 1994-10-31 1994-10-31 Method for treating anxiety
US08/336,589 US5484794A (en) 1994-11-09 1994-11-09 Method for treating anxiety

Publications (2)

Publication Number Publication Date
DE69516075D1 true DE69516075D1 (de) 2000-05-11
DE69516075T2 DE69516075T2 (de) 2000-09-14

Family

ID=26988105

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69516075T Expired - Fee Related DE69516075T2 (de) 1994-10-31 1995-10-30 Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen

Country Status (13)

Country Link
US (1) US5726193A (de)
EP (1) EP0709093B1 (de)
JP (1) JPH10508027A (de)
AT (1) ATE191343T1 (de)
AU (1) AU4017295A (de)
CA (1) CA2202781A1 (de)
DE (1) DE69516075T2 (de)
DK (1) DK0709093T3 (de)
ES (1) ES2144582T3 (de)
GR (1) GR3033783T3 (de)
IL (1) IL115810A0 (de)
PT (1) PT709093E (de)
WO (1) WO1996013166A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
AU1128297A (en) * 1995-12-06 1997-06-27 Eli Lilly And Company Composition for treating pain
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
CZ285030B6 (cs) * 1993-08-19 1999-05-12 Novo Nordisk A/S Použití thiadiazolových a oxadiazolových sloučenin pro výrobu farmaceutického prostředku a farmacetický prostředek pro léčení schizofrenie nebo schizofrenních nemocí
PT714394E (pt) * 1993-08-19 2001-12-28 Novo Nordisk As Metodo antipsicotico com derivados de tiadiazol e oxadiazol

Also Published As

Publication number Publication date
EP0709093A3 (de) 1996-05-29
EP0709093B1 (de) 2000-04-05
IL115810A0 (en) 1996-01-19
ES2144582T3 (es) 2000-06-16
US5726193A (en) 1998-03-10
DE69516075T2 (de) 2000-09-14
EP0709093A2 (de) 1996-05-01
WO1996013166A1 (en) 1996-05-09
PT709093E (pt) 2000-08-31
AU4017295A (en) 1996-05-23
GR3033783T3 (en) 2000-10-31
JPH10508027A (ja) 1998-08-04
DK0709093T3 (da) 2000-07-10
CA2202781A1 (en) 1996-05-09
ATE191343T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
ES8503351A1 (es) Un procedimiento para preparar nuevos derivados de imidazo (4,5-c) piridina (como divisional de la solicitud de patente de invencion num. 517.193, presentada el 8 de noviembre de 1982)
BG102792A (en) Substituted derivatives of 4-hydroxyphenylalkane acids having antagonists activity to ppar-gama.
NO169286C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater
ATE527247T1 (de) Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
ATE191344T1 (de) Tetrahydropyridin oxadiazol- oder -thiadiazol- verbindung zur behandlung von angstzuständen
ATE191343T1 (de) Verwendung von einem azabicyclischen oxadiazol- oder -thiadiazol-verbindung zur behandlung von angstzuständen
NO168890C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive acylcephalosporinderivater
HUP0004644A2 (hu) Neutrofil elasztáz inhibitor hatású pirrolo-pirrolon-származékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
ATE84532T1 (de) Cyclische amide.
NO872382D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
AU560286B2 (en) Imidazobenzodiazepines
DK283487D0 (da) Thiazolyl-2-yl-imidazo(1,2-a)pyrimidiner, deres fremstilling og brug
HUP0203622A2 (hu) Biciklusos vazopresszin agonisták és ezeket tartalmazó gyógyszerkészítmények
DK0573318T3 (da) 4-phenylcarbamoyl-3-isoxazolcarboxylsyreforbindelser, fremgangsmåde til deres fremstilling, farmaceutiske præparater med in
SE8306112L (sv) Biologiskt aktiva peptider
FI861951A0 (fi) 1,3-oxatianderivat.
ES8604843A1 (es) Un metodo para la preparacion de un derivado de acetileno
ES8802507A1 (es) Procedimiento para preparar eteres 1,3-dioxano.
DE69523819T2 (de) Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
NO161440C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrimidin-2-oner.
DE69617444T2 (de) Heterocyclische verbindungen zur schmerzbehandlung und deren verwendung
HUP0002054A2 (hu) N-4-(nitro-metil-szulfonil)-fenil-alkánamid és -benzolszulfonamid-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ES2005778A6 (es) Procedimiento para la obtencion de derivados de diisobutilxantina.
ES8704959A1 (es) Procedimiento para la obtencion de heterociclos que contienen fosforo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee